Advanced search
Publication Cover
Emerging Microbes & Infections Volume 7, 2018 - Issue 1
Submit an article Journal homepage
1,111
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor

Bin JuSchool of MedicineNankai University300071TianjinChina;Nankai University Second People’s Hospital, School of MedicineNankai University300071TianjinChina;State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Dan LiState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Li RenState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Jiali HouState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Yanling HaoState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Hua LiangState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Shuo WangState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChina
,
Jiang ZhuDepartment of Immunology and Microbial ScienceThe Scripps Research Institute92037La JollaCAUSA
,
Min WeiSchool of MedicineNankai University300071TianjinChina;Nankai University Second People’s Hospital, School of MedicineNankai University300071TianjinChinaCorrespondence[email protected]
&
Yiming ShaoSchool of MedicineNankai University300071TianjinChina;State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases102206BeijingChinaCorrespondence[email protected]
 show all
Pages 1-12 | Received 17 Apr 2018, Accepted 14 Sep 2018, Published online: 01 Nov 2018

References

  • GaschenBDiversity considerations in HIV-1 vaccine selectionScience2002296 2354 236010.1126/science.1070441
  • WalkerBDKorberBTImmune control of HIV: the obstacles of HLA and viral diversityNat. Immunol.2001247347510.1038/88656
  • BarouchDHChallenges in the development of an HIV-1 vaccineNature200845561361910.1038/nature07352
  • LuLThe changing face of HIV in ChinaNature200845560961110.1038/nature07263
  • QiaoYIsolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120Antiviral Res.201613225226110.1016/j.antiviral.2016.06.013
  • StamatatosLMorrisLBurtonDRMascolaJRNeutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?Nat. Med.20091586687010.1038/nm.1949
  • SatherDNFactors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infectionJ. Virol.20098375776910.1128/JVI.02036-08
  • Doria-RoseNABreadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesJ. Virol.2010841631163610.1128/JVI.01482-09
  • WuXRational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Science201032985686110.1126/science.1187659
  • WuXFocused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencingScience20113331593160210.1126/science.1207532
  • WalkerLMBroad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetScience200932628528910.1126/science.1178746
  • WalkerLMBroad neutralization coverage of HIV by multiple highly potent antibodiesNature201147746647010.1038/nature10373
  • HuangJBroad and potent neutralization of HIV-1 by a gp41-specific human antibodyNature201249140641210.1038/nature11544
  • HuangJBroad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceNature201451513814210.1038/nature13601
  • KongRFusion peptide of HIV-1 as a site of vulnerability to neutralizing antibodyScience201635282883310.1126/science.aae0474
  • KongLKey gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese DonorImmunity20164493995010.1016/j.immuni.2016.03.006
  • SunYQiaoYZhuYChongHHeY. Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donorOncotarget2017863047630635609902
  • MurphyEDiversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African RepublicAIDS Res. Hum. Retroviruses19939997100610.1089/aid.1993.9.997
  • LiaoHPhylodynamic analysis of the dissemination of HIV-1 CRF01_AE in VietnamVirology2009391515610.1016/j.virol.2009.05.023
  • McCutchanFEGenetic variants of HIV-1 in ThailandAIDS Res. Hum. Retroviruses199281887189510.1089/aid.1992.8.1887
  • NelsonKERisk factors for HIV infection among young adult men in northern ThailandJAMA199327095596010.1001/jama.1993.03510080059032
  • CarrJKFull-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from ThailandJ. Virol.19967059355943190613
  • HemelaarJGouwsEGhysPDOsmanovSGlobal and regional distribution of HIV-1 genetic subtypes and recombinants in 2004AIDS200620W13W2310.1097/01.aids.0000247564.73009.bc
  • YeJPhylogenetic and temporal dynamics of human immunodeficiency virus type 1 CRF01_AE in ChinaPLoS ONE20138e5423810.1371/journal.pone.0054238
  • ChenJHIV type 1 subtypes in Guangxi Province, China, 1996AIDS Res. Hum. Retroviruses199915818410.1089/088922299311754
  • ChengHZhangJCapizziJYoungNLMastroTDHIV-1 subtype E in Yunnan, ChinaLancet199434495395410.1016/S0140-6736(94)92304-3
  • HeXA comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic surveyPLoS ONE20127e4728910.1371/journal.pone.0047289
  • HuXProfiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B’-infected former plasma donors from China naive to antiretroviral therapyJ. Gen. Virol.2012932267227810.1099/vir.0.043802-0
  • HuXProfiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naive to antiretroviral therapySci. Rep.2017710.1038/srep46308
  • MascolaJRMontefioriDCThe role of antibodies in HIV vaccinesAnnu. Rev. Immunol.20102841344410.1146/annurev-immunol-030409-101256
  • GoepfertPADurable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersVaccine20072551051810.1016/j.vaccine.2006.07.050
  • RussellNDPhase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination withrgp120: negative results fail to trigger a phase 3 correlates trialJ. Acquir. Immune Defic. Syndr.20074420321210.1097/01.qai.0000248356.48501.ff
  • SandersRWHIV-1 neutralizing antibodies induced by native-like envelope trimersScience2015349aac422310.1126/science.aac4223
  • MoldtBHighly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoProc. Natl Acad. Sci. USA2012109189211892510.1073/pnas.1214785109
  • LiuJAntibody-mediated protection against SHIV challenge includes systemic clearance of distal virusScience20163531045104910.1126/science.aag0491
  • MoldtBNeutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaquesAIDS2016301543155110.1097/QAD.0000000000001102
  • XuLTrispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaquesScience2017358859010.1126/science.aan8630
  • BoltonDLHuman Immunodeficiency Virus Type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirsJ. Virol.2015901321133210.1128/JVI.02454-15
  • Julg, B. et al. Virological control by the CD4-binding site antibody n6 in simian-human immunodeficiency virus-infected rhesus monkeys. J. Virol.91, pii: e00498-17 (2017).
  • LynchRMVirologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionSci. Transl. Med.20157319ra20610.1126/scitranslmed.aad5752
  • HuangJIdentification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadthImmunity2016451108112110.1016/j.immuni.2016.10.027
  • FalkowskaEBroadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimersImmunity20144065766810.1016/j.immuni.2014.04.009
  • BlattnerCStructural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimersImmunity20144066968010.1016/j.immuni.2014.04.008
  • MayerKHSafety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialPLoS Med.201714e100243510.1371/journal.pmed.1002435
  • GaudinskiMRSafety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adultsPLoS Med.201815e100249310.1371/journal.pmed.1002493
  • ZhouTStructural basis for broad and potent neutralization of HIV-1 by antibody VRC01Science201032981181710.1126/science.1192819
  • ZhouTMultidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodiesImmunity20133924525810.1016/j.immuni.2013.04.012
  • JardineJRational HIV immunogen design to target specific germline B cell receptorsScience201334071171610.1126/science.1234150
  • Medina-RamirezMDesign and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivoJ. Exp. Med.20172142573259010.1084/jem.20161160
  • KongLUncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastabilityNat. Commun.2016710.1038/ncomms12040
  • TillerTEfficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloningJ. Immunol. Methods200832911212410.1016/j.jim.2007.09.017
  • WuXMaturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infectionCell201516147048510.1016/j.cell.2015.03.004
  • LiMHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesJ. Virol.200579101081012510.1128/JVI.79.16.10108-10125.2005
  • deCampAGlobal panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesJ. Virol.2014882489250710.1128/JVI.02853-13
  • FengYBiochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding siteJ. Biol. Chem.20122875673568610.1074/jbc.M111.317776

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.